Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on International Tech Times.
Press releases published on March 12, 2025
PyroWorld: The Next Evolution in Hybrid Crypto Exchange – Licensed, Secure, and Expanding with AI & OTC Solutions
GlobeNewswire
·
March 12, 2025
Prague, Czech Republic, March 12, 2025 (GLOBE NEWSWIRE) -- PyroWorld, a licensed European hybrid crypto exchange, is expanding its suite of regulated financial solutions, integrating OTC trading, AI-driven analytics, and decentralized swap services. As the …
OBI Pharma reçoit le prix du « Candidat clinique ADC le plus prometteur à Taïwan »
GlobeNewswire
·
March 12, 2025
TAIPEI, Taïwan, 12 mars 2025 (GLOBE NEWSWIRE) -- Lors du congrès ADC Asia 2025, qui s’est déroulé aujourd’hui (12 mars) à Singapour, la société OBI Pharma (4174.TWO) a reçu le prix du « Candidat clinique ADC le plus prometteur à Taïwan ». Cette distinction …
OBI Pharma erhält Auszeichnung als „vielversprechendster AWK-Kandidat für klinische Studien in Taiwan“
GlobeNewswire
·
March 12, 2025
TAIPEH, Taiwan, March 12, 2025 (GLOBE NEWSWIRE) -- Auf dem ADC Asia Congress 2025, der heute (12.03.) in Singapur stattgefundenhat, wurde OBI Pharma (4174.TWO) mit dem Preis „Vielversprechendster AWK-Kandidat für klinische Studien in Taiwan“ ausgezeichnet. …
OBI Pharma Receives ‘Most Promising ADC Clinical Candidate in Taiwan’ Award
GlobeNewswire
·
March 12, 2025
TAIPEI, Taiwan, March 12, 2025 (GLOBE NEWSWIRE) -- At the ADC Asia Congress 2025 held today (3/12) in Singapore, OBI Pharma (4174.TWO) was honored with the "Most Promising ADC Clinical Candidate in Taiwan" award. This recognition follows OBI Pharma’s …
浩鼎 荣获「台湾最具潜力 ADC 临床候选药物奖」
GlobeNewswire
·
March 12, 2025
台湾台北, March 12, 2025 (GLOBE NEWSWIRE) -- 今（3/12）在新加坡举行的「2025亚洲ADC大会」（ADC Asia Congress 2025）晚会宣布，台湾浩鼎生技（4174.TWO）荣获「台湾最具潜力 ADC 临床候选药物奖（Most Promising ADC Clinical Candidate in Taiwan）」；这是自去年底，与国际药厂共同入围「世界ADC大奖」全球前八强之后，浩鼎开发ADC（抗体药物复合体）新药的实力，再度获得国际专业领域肯定。 …
浩鼎 榮獲「台灣最具潛力 ADC 臨床候選藥物獎」
GlobeNewswire
·
March 12, 2025
台灣台北, March 12, 2025 (GLOBE NEWSWIRE) -- 今（3/12）在新加坡舉行的「2025亞洲ADC大會」（ADC Asia Congress 2025 ）晚會宣布，台灣浩鼎生技（4174.TWO）榮獲「台灣最具潛力 ADC 臨床候選藥物獎 （Most Promising ADC Clinical Candidate in Taiwan）」；這是自去年底，與國際藥廠共同入圍「世界ADC大獎」全球前八強之後，浩鼎開發ADC（抗體藥物複合體）新藥的實力，再度獲得國際專業領域肯定。 …
Grand Canyon National Park is the most visited National Park in USA according to the Travel App, Visited
GlobeNewswire
·
March 12, 2025
TORONTO, March 12, 2025 (GLOBE NEWSWIRE) -- The where I’ve been app, Visited, publishes the most popular National Parks (as well as important places in US that are managed by National Parks) as per international and domestic travelers. The popular travel …
Emergency Medical Service Products Market to Reach USD 62 Billion by 2035, Growing at a 6.4% CAGR | Fact.MR Report
GlobeNewswire
·
March 12, 2025
Rockville, MD, March 12, 2025 (GLOBE NEWSWIRE) -- According to Fact.MR, The global emergency medical service products market was valued at USD 31 billion in 2024 and is projected to register a noteworthy CAGR of 6.4% to end up at USD 62 billion by 2035. …
Atsena Therapeutics Granted U.S. FDA Fast Track Designation for ATSN-201 Gene Therapy to Treat X-linked Retinoschisis
GlobeNewswire
·
March 12, 2025
DURHAM, N.C., March 12, 2025 (GLOBE NEWSWIRE) -- Atsena Therapeutics, a clinical-stage gene therapy company focused on using the life-changing power of genetic medicine to reverse or prevent blindness, today announced that the U.S. Food and Drug …
Theratechnologies présente des données de suppression virologique encourageantes provenant de l’essai PROMISE-US portant sur l’ibalizumab lors de la CROI
GlobeNewswire
·
March 12, 2025
Les résultats montrent des niveaux semblables de charge virale indétectable chez les patients qui reçoivent des traitements comprenant de l’ibalizumab que chez les témoins, malgré un degré de gravité initial du VIH supérieur L’ibalizumab continue de …
Theratechnologies CROI Presentation Highlights Limitations of Using BMI to Assess Cardiovascular (CV) Risk in People with HIV
GlobeNewswire
·
March 12, 2025
MONTREAL, March 12, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today presented data highlighting the limitations of using body mass index ( …
La présentation de Therachnologies lors de la CROI met en évidence les limites liées à l’utilisation de l’IMC pour évaluer le risque de maladie cardiovasculaire (CV) chez les personnes vivant avec le VIH
GlobeNewswire
·
March 12, 2025
MONTRÉAL, 12 mars 2025 (GLOBE NEWSWIRE) -- Theratechnologies inc. (« Theratechnologies » ou la « Société ») (TSX : TH) (NASDAQ : THTX), une société biopharmaceutique au stade commercial, a présenté aujourd’hui des données mettant en évidence les limites …
Theratechnologies Presents Encouraging Virologic Suppression Data from the PROMISE-US Trial of Ibalizumab at CROI
GlobeNewswire
·
March 12, 2025
Results show similar levels of virus undetectability in patients on ibalizumab-containing regimens as in controls, despite greater baseline severity of HIV Ibalizumab continues to demonstrate long-term efficacy and safety as part of combination …
OptimizeRx Reports Strong Fourth Quarter and Full Year 2024 Financial Results
GlobeNewswire
·
March 12, 2025
Q4 revenue of $32.3 million, increasing 14% year-over-year Q4 gross profit increased 23% year-over-year to $22.0 million with gross margin of 68% Company generated revenue from 48 DAAP deals in 2024, up from 24 in 2023 WALTHAM, Mass., March 12, 2025 (GLOBE …
American Tungsten Corp. Identifies Principal Exploration Target for the IMA Mine Project in Idaho, USA
GlobeNewswire
·
March 12, 2025
Vancouver, BC, March 12, 2025 (GLOBE NEWSWIRE) -- American Tungsten Corp. (CSE:TUNG) (OTCQB:DEMRF) (FSE:RK9) (“American Tungsten” or the “Company”) announced that it has identified a principal tungsten exploration target on the IMA Mine and is initiating …
JOYY to Announce Fourth Quarter and Full Year 2024 Financial Results on March 19, 2025
GlobeNewswire
·
March 12, 2025
SINGAPORE, March 12, 2025 (GLOBE NEWSWIRE) -- JOYY Inc. (NASDAQ: YY) (“JOYY” or the “Company”), a global technology company, today announced that it plans to release its fourth quarter and full year 2024 financial results after the U.S. market closes on …
Sagimet Biosciences Reports Full Year 2024 Financial Results and Provides Corporate Updates
GlobeNewswire
·
March 12, 2025
Denifanstat Phase 3 MASH program initiated in Q4 2024; patient screening expected to start in 1H 2025 Denifanstat received Breakthrough Therapy designation from FDA for MASH Clearance of Investigational New Drug (IND) application for FASN Inhibitor TVB- …
Mesoblast CEO to Deliver Featured Presentation at ISCT North America Virtual Town Hall
GlobeNewswire
·
March 12, 2025
NEW YORK, March 12, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced today that Chief Executive Silviu Itescu will deliver the Featured Presentation at …
Crypto Cards Go Non-Custodial With GoDefi, Announces Second Funding Round Following Initial Launch Success
GlobeNewswire
·
March 12, 2025
Prague, Czech Republic , March 12, 2025 (GLOBE NEWSWIRE) -- A centralized spending experience with decentralization at its core, GoDefi offers virtual debit cards that users can connect with their favorite crypto wallet. In a world where spending crypto in …
Harvard Bioscience Announces Fourth Quarter and Full-Year 2024 Financial Results
GlobeNewswire
·
March 12, 2025
HOLLISTON, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the fourth quarter and full year ended December 31, 2024. Jim Green, Chairman and CEO, said, “Our fourth …